CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
SLIDE-HCC: Phase II trial of STRIDE (durvalumab + tremelimumab) + lenvatinib vs STRIDE in patients with unresectable hepatocellular carcinoma
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Docetaxel and Hormone Treatment compared to Hormone Treatment alone in people with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response (TRIPLE-SWITCH)
The CCTG BRC5 abstract was presented at the 2022 World Conference on Lung Cancer in Vienna, Austria as a Plenary 3: Presidential Symposium - Top Rated Abstracts. The presentation concluded that Sublobar resection (including wedge) are equivalent to lobectomy for stage I lung cancer <2cm. There is the potential that this could become a new standard of care with no difference in DFS or OS and similar rates of recurrence.
CCTG MAC22 TMIST - Tomosynthesis Mammographic Imaging Screening Trial (NCT03233191) has accrued an impressive 10,027 Canadians to the study. Congratulations to the trial team and all of the participating centers across Canada.
A new CCTG national study has received funding from the Social Sciences and Humanities Research Council and Genome Canada to explore the ethical questions raised with emerging cancer technologies like CAR-T cell therapy.
Please be aware that the trial PA6: Multicentre Randomized Phase III Trial Comparing 6-Month Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) In Patients With Resected Pancreatic Adenocarcinoma has been permanently closed.
Trial-specific DSMC Summary Reports are now posted on trial websites. Single-study centres participating on these trials should download these reports and submit them to their Research Ethics Boards if required by local policy. Trials currently under CCTG's DSMC oversight include:
Objectives: Primary: To determine the incremental cost-utility ratio of an early novel therapy approach (venetoclax-obinutuzumab) compared to a deferred approach in Canadian patients with high-risk CLL.
CCTG would like to welcome Bill Richardson a new Patient Representative who will be working with the Head and Neck disease site committee. Bill is located in Calgary with a microbiologist background and has worked in government, private industry, teaching and later moved to IT spending 30 years in the Kinesiology Faculty at the University of Calgary.
